HHLA2 Inhibitors
HHLA2 inhibitors comprise a range of chemicals that curtail the activity of HHLA2 through various signaling pathways. Staurosporine, as a broad-spectrum protein kinase inhibitor, primarily targets PKC, potentially attenuating the phosphorylation of proteins that could be co-factors or regulators of HHLA2, thus leading to its functional inhibition. Concurrently, LY 294002 and Wortmannin, by inhibiting PI3K, decrease AKT pathway signaling, potentially leading to a reduction in the cellular processes such as survival and proliferation, which could be necessary for HHLA2 activity. U0126 and PD 98059, both targeting the MEK1/2 in the MAPK/ERK pathway, might alter the signaling environment and diminish HHLA2's functional capacity, while SB 203580 and SP600125, targeting p38 MAPK and JNK respectively, could impact stress response and inflammatory pathways, thereby indirectly inhibiting HHLA2's functionality.
Rapamycin, by targeting mTOR, may affect the cell growth and survival pathways, possibly leading to the downregulation of HHLA2's activity. Gefitinib and Erlotinib, both EGFR inhibitors, have the potential to alter EGFR signaling, which is a crucial modulator of cellular microenvironment and could be criticalfor HHLA2's functional involvement. Additionally, Sorafenib's inhibition of Raf kinase disrupts the downstream MEK/ERK pathway, which might affect the cellular signaling that potentially impacts HHLA2 function. Imatinib, by targeting multiple tyrosine kinases including BCR-ABL, c-KIT, and PDGFR, is capable of altering various signaling pathways, thereby indirectly inhibiting HHLA2 by changing the cellular context in which it operates. Collectively, these inhibitors exert their influence through multiple cellular signaling pathways, converging to decrease the functional activity of HHLA2 without directly binding to or altering the protein itself.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
A potent protein kinase inhibitor that can indirectly inhibit HHLA2 by inhibiting Protein Kinase C (PKC), which is possibly involved in the phosphorylation of proteins that may interact with HHLA2, leading to its functional inhibition. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A phosphoinositide 3-kinases (PI3K) inhibitor that can diminish HHLA2 signaling by reducing the PI3K/AKT pathway activity, which is involved in cell survival and proliferation, potentially leading to reduced functional activity of HHLA2. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
A specific inhibitor of MEK1/2 which indirectly inhibits HHLA2 by affecting the MAPK/ERK pathway, potentially altering the cellular context in which HHLA2 operates, thus diminishing its functional activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor that can indirectly diminish HHLA2 activity by inhibiting the mTOR pathway, which is involved in cell growth and survival, potentially affecting HHLA2's functional activity within these processes. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
An MEK inhibitor that may indirectly inhibit HHLA2 by blocking the MAPK/ERK pathway, potentially affecting the signaling environment that influences HHLA2 activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
A p38 MAPK inhibitor that can indirectly diminish HHLA2 function by inhibiting p38 MAPK, potentially affecting stress response pathways and cytokine production that may influence HHLA2 activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
A JNK inhibitor that can indirectly inhibit HHLA2 activity by affecting the JNK signaling pathway, potentially altering apoptosis and inflammatory responses that may impact HHLA2 functional activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
A PI3K inhibitor that can indirectly diminish HHLA2 activity by inhibiting the PI3K/AKT pathway, which may affect cellular processes such as survival, proliferation, and migration that are relevant to HHLA2 function. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
An EGFR tyrosine kinase inhibitor that can indirectly inhibit HHLA2 by decreasing EGFR signaling, which may impact cellular processes and the microenvironment where HHLA2 functions. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
An EGFR inhibitor that can indirectly inhibit HHLA2 by affecting EGFR-mediated signaling pathways, potentially altering cellular contexts that influence HHLA2 activity. | ||||||